| |
Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities.
|
|
Today’s Big NewsSep 19, 2023 |
|
Avoid costly manufacturing delays by establishing the identity, purity and quality of your starting materials. Download this comprehensive guide to raw materials testing. Learn more.
|
|
| By Gabrielle Masson GSK’s Senior Vice President and Head of Research John Lepore, M.D., has left the company at the same time the U.K. pharma undergoes a slight shuffling of its R&D operations. |
|
|
|
By Annalee Armstrong Biopharmas looking to submit a drug for approval to the FDA based on just one clinical trial better be thorough in the data they include—good and bad—and they should get in touch with the agency as early as possible. |
By James Waldron Two months after halting its remaining development program in a last-ditch attempt to conserve cash, Histogen has run out of options and will wind down. |
Sponsored by Rise to Health Coalition Two leaders supporting the Rise to Health Coalition discuss the need for coordinated and collective action across sectors to advance health equity |
|
BioIVT’s NA ISSX presentations covered multiple important topics this year, including phase I and phase II activities in hepatocytes and microsomes based on donor diversity… Read More >>
|
|
By Nick Paul Taylor Kinnate Biopharma is cutting deep. Months after its delayed cancer data disappointed investors, the biotech has revealed it is laying off 70% of its staff and narrowing its pipeline to stretch its cash reserves into the second quarter of 2026. |
By Nick Paul Taylor Guard Therapeutics is mounting a bullish bounce back from the failure of its phase 2 kidney injury clinical trial. A primary endpoint failure brought the study to an early end, but the Swedish biotech branded that setback “irrelevant” Tuesday, arguing that longer-term efficacy assessments show its asset has a future. |
By Max Bayer A dwindling COVID-19 vaccine market is not stopping Arcturus Therapeutics from pressing ahead with its own mRNA candidate, as the biotech touts new early data indicating its shot lights up the immune system. |
By James Waldron It’s been a good week for Scancell’s shareholders, as investors seized on early data from the biotech's phase 2 cancer vaccine trial to send its stock up 20%. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Kevin Dunleavy A survey of 100 doctors in the U.S. who prescribe weight loss medications shows that more than 75% consider new obesity drugs from Eli Lilly and Novo Nordisk as “paradigm shifting.” But the physicians also have significant concerns about the cost of the treatments, patient eligibility for coverage and long-term safety risks. |
By Conor Hale The observational study showed that Jada was able to rapidly control postpartum hemorrhage—a major cause of maternal morbidity in the U.S.—including in women who had a vaginal delivery as well as those who underwent a C-section. |
By Angus Liu Novartis has ended its major cancer immunotherapy collaboration with BeiGene more than two years after touting the benefits of having a PD-1 inhibitor. |
By Joseph Keenan Biofourmis, a Boston-based digital therapeutics company, debuted an expanded version of its digital clinical trials platform designed to speed drug development and increase patient diversity. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we take a closer look at the challenges with new email policies, and the importance of diverse investors and founders. |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200
|
|
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
